1. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA: A Cancer Journal for Clinicians. 2018;68(4):297-316. DOI: 10.3322/caac.21446
2. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Research and Treatment. 1998;52(1–3):239-259. DOI: 10.1023/a:1006137619153
3. Quaglino F, Marchese V, Lemini R, Piovesan A, Mazza E, Viora T, et al. Parathyroid carcinoma. A single Institution experience and a review of the international literature. Annali Italiani di Chirurgia. 2018;89:295-304
4. Jia X, Zhao Q, Zhang Y, Dong Y, Lei L, Williamson RA, et al. Identification of a five-CpG signature with diagnostic value in thyroid cancer. Journal of Computational Biology. 2019;26(12):1409-1417. DOI: 10.1089/cmb.2019.0165
5. D’Cruz AK, Vaish R, Vaidya A, Nixon IJ, Williams MD, Vander Poorten V, et al. Molecular markers in well-differentiated thyroid cancer. European Archives of Oto-Rhino-Laryngology. 2018;275(6):1375-1384. DOI: 10.1007/s00405-018-4944-1